273 related articles for article (PubMed ID: 30104289)
1. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K; Grapsa D; Sangare R; Evmorfiadis I; Larsen AK; Van Dreden P; Boura P; Charpidou A; Kotteas E; Sergentanis TN; Elalamy I; Falanga A; Gerotziafas GT
Oncologist; 2018 Nov; 23(11):1372-1381. PubMed ID: 30104289
[TBL] [Abstract][Full Text] [Related]
2. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
Fotiou D; Sergentanis TN; Papageorgiou L; Stamatelopoulos K; Gavriatopoulou M; Kastritis E; Psaltopoulou T; Salta S; Van Dreden P; Sangare R; Larsen AK; Terpos E; Elalamy I; Dimopoulos MA; Gerotziafas GT
Blood Cancer J; 2018 Nov; 8(11):102. PubMed ID: 30405097
[TBL] [Abstract][Full Text] [Related]
3. Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study.
Gerotziafas GT; Zografos T; Pantos I; Lefkou E; Carlo A; Fareed J; Van Dreden P; Katritsis D
Clin Appl Thromb Hemost; 2020; 26():1076029620964590. PubMed ID: 33284037
[TBL] [Abstract][Full Text] [Related]
4. PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study.
Boura P; Evmorfiadis I; Rousseau A; Charpidou A; Giozos G; Van Dreden P; Syrigos K; Larsen A; Elalamy I; Gerotziafas GT
Thromb Res; 2016 Apr; 140 Suppl 1():S196. PubMed ID: 27161741
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.
Riva N; Vella K; Hickey K; Bertù L; Zammit D; Spiteri S; Kitchen S; Makris M; Ageno W; Gatt A
J Clin Pathol; 2018 Nov; 71(11):1015-1022. PubMed ID: 30093507
[TBL] [Abstract][Full Text] [Related]
6. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.
Chaari M; Ayadi I; Rousseau A; Lefkou E; Van Dreden P; Sidibe F; Ketatni H; Galea V; Khaterchi A; Bouzguenda R; Frikha M; Ghorbal L; Daoud J; Kallel C; Quinn M; Gligorov J; Lotz JP; Hatmi M; Elalamy I; Gerotziafas GT
BMC Cancer; 2014 Dec; 14():991. PubMed ID: 25535397
[TBL] [Abstract][Full Text] [Related]
7. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.
Gerotziafas GT; Taher A; Abdel-Razeq H; AboElnazar E; Spyropoulos AC; El Shemmari S; Larsen AK; Elalamy I;
Oncologist; 2017 Oct; 22(10):1222-1231. PubMed ID: 28550032
[TBL] [Abstract][Full Text] [Related]
8. Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study.
Gerotziafas GT; Van Dreden P; Mathieu d'Argent E; Lefkou E; Grusse M; Comtet M; Sangare R; Ketatni H; Larsen AK; Elalamy I
Thromb J; 2017; 15():9. PubMed ID: 28360822
[TBL] [Abstract][Full Text] [Related]
9. Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Papageorgiou C; Vandreden P; Marret E; Bonnet F; Robert F; Spyropoulos A; Galea V; Elalamy I; Hatmi M; Gerotziafas GT
Thromb Res; 2013 Nov; 132(5):584-91. PubMed ID: 24094602
[TBL] [Abstract][Full Text] [Related]
10. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.
Marchetti M; Tartari CJ; Russo L; Panova-Noeva M; Leuzzi A; Rambaldi A; Finazzi G; Woodhams B; Falanga A
Am J Hematol; 2014 Jan; 89(1):68-73. PubMed ID: 24009132
[TBL] [Abstract][Full Text] [Related]
11. External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.
Spyropoulos AC; Eldredge JB; Anand LN; Zhang M; Qiu M; Nourabadi S; Rosenberg DJ
Oncologist; 2020 Jul; 25(7):e1083-e1090. PubMed ID: 32017293
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.
Schorling RM; Pfrepper C; Golombek T; Cella CA; Muñoz-Unceta N; Siegemund R; Engel C; Petros S; Lordick F; Knödler M
Oncol Res Treat; 2020; 43(9):414-427. PubMed ID: 32580190
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
[TBL] [Abstract][Full Text] [Related]
14. Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events.
Campello E; Zabeo E; Radu CM; Spiezia L; Gavasso S; Fadin M; Woodhams B; Vettor R; Simioni P
Thromb Haemost; 2015 Jan; 113(1):85-96. PubMed ID: 25318550
[TBL] [Abstract][Full Text] [Related]
15. VIIaAT complexes, procoagulant phospholipids, and thrombin generation during postprandial lipemia.
Silveira A; Carlo A; Adam M; McLeod O; Lundman P; Boquist S; Woodhams BJ; Hamsten A
Int J Lab Hematol; 2018 Jun; 40(3):251-257. PubMed ID: 29356352
[TBL] [Abstract][Full Text] [Related]
16. Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S.
Campello E; Spiezia L; Radu CM; Bulato C; Gavasso S; Tormene D; Woodhams B; Dalla Valle F; Simioni P
Thromb Haemost; 2016 Jan; 115(1):81-8. PubMed ID: 26354831
[TBL] [Abstract][Full Text] [Related]
17. 28 day post-operative persisted hypercoagulability after surgery for benign diseases: a prospective cohort study.
Ulrych J; Kvasnicka T; Fryba V; Komarc M; Malikova I; Burget F; Brzezkova R; Kvasnicka J; Krska Z; Kvasnicka J
BMC Surg; 2016 Apr; 16():16. PubMed ID: 27048604
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.
Reitter EM; Kaider A; Ay C; Quehenberger P; Marosi C; Zielinski C; Pabinger I
J Thromb Haemost; 2016 Feb; 14(2):294-305. PubMed ID: 26662117
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
[TBL] [Abstract][Full Text] [Related]
20. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Gerotziafas GT; Van Dreden P; Chaari M; Galea V; Khaterchi A; Lionnet F; Stankovic-Stojanovic K; Blanc-Brude O; Woodhams B; Maier-Redelsperger M; Girot R; Hatmi M; Elalamy I
Thromb Haemost; 2012 Jun; 107(6):1044-52. PubMed ID: 22535498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
